As of 2025-05-18, the EV/EBITDA ratio of Hainan Shuangcheng Pharmaceuticals Co Ltd (002693.SZ) is -35.64. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 002693.SZ's latest enterprise value is 3,095.36 mil CNY. 002693.SZ's TTM EBITDA according to its financial statements is -86.84 mil CNY. Dividing these 2 quantities gives us the above 002693.SZ EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 25.2x - 32.4x | 28.5x |
| Forward P/E multiples | 11.2x - 14.1x | 13.8x |
| Fair Price | (5.67) - (3.36) | (4.83) |
| Upside | -180.4% - -147.6% | -168.5% |
| Date | EV/EBITDA |
| 2025-02-14 | -83.39 |
| 2025-02-13 | -84.92 |
| 2025-02-12 | -77.38 |
| 2025-02-11 | -74.89 |
| 2025-02-10 | -76.52 |
| 2025-02-07 | -69.74 |
| 2025-02-06 | -68.11 |
| 2025-02-05 | -65.92 |
| 2025-01-27 | -64.34 |
| 2025-01-24 | -65.49 |
| 2025-01-23 | -66.78 |
| 2025-01-22 | -66.78 |
| 2025-01-21 | -70.02 |
| 2025-01-20 | -73.08 |
| 2025-01-17 | -78.05 |
| 2025-01-16 | -78.86 |
| 2025-01-15 | -78.29 |
| 2025-01-14 | -81.05 |
| 2025-01-13 | -76.95 |
| 2025-01-10 | -74.51 |
| 2025-01-09 | -78.71 |
| 2025-01-08 | -80.00 |
| 2025-01-07 | -79.62 |
| 2025-01-06 | -79.91 |
| 2025-01-03 | -88.55 |
| 2025-01-02 | -98.20 |
| 2024-12-31 | -89.46 |
| 2024-12-30 | -84.35 |
| 2024-12-27 | -87.88 |
| 2024-12-26 | -86.12 |
| 2024-12-25 | -87.98 |
| 2024-12-24 | -91.94 |
| 2024-12-23 | -92.99 |
| 2024-12-20 | -101.59 |
| 2024-12-19 | -101.06 |
| 2024-12-18 | -104.07 |
| 2024-12-17 | -101.87 |
| 2024-12-16 | -108.89 |
| 2024-12-13 | -105.55 |
| 2024-12-12 | -109.99 |
| 2024-12-11 | -110.28 |
| 2024-12-10 | -109.18 |
| 2024-12-09 | -108.85 |
| 2024-12-06 | -112.43 |
| 2024-12-05 | -115.34 |
| 2024-12-04 | -114.15 |
| 2024-12-03 | -117.97 |
| 2024-12-02 | -119.21 |
| 2024-11-29 | -111.57 |
| 2024-11-28 | -111.19 |